TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04591028
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A one time injection of IDC prior to the day of scheduled surgery.
Study: NCT05540912
Drug: CKD-828 Formulation 1
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 1
Study: NCT06244550
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets
Study: NCT05662332
Drug: Insulin Efsitora Alfa
Normalized name: Insulin efsitora alfa
DrugBank: Insulin efsitora alfa (DB19013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05662332
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT06579274
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
Study: NCT06389305
Drug: peripheral blood lymphocytes
Normalized name: Autologous Human Peripheral Blood Lymphocytes
DrugBank: Autologous Human Peripheral Blood Lymphocytes (DB17089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous or allogeneic peripheral blood lymphocytes
Study: NCT05325190
Drug: Granisetron Transdermal Patch System
Normalized name: granisetron Transdermal System
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
Study: NCT05654870
Drug: Valbenazine
Normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral treatment
Study: NCT06684158
Drug: Mecapegfilgrastim
Normalized name: Mecapegfilgrastim
DrugBank: Mecapegfilgrastim (DB19147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg,HD d3,every 2weeks (Q2W)
Study: NCT06684158
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)
Study: NCT06684158
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Study: NCT06684158
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)
Study: NCT06684158
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)
Study: NCT05263271
Drug: Gentulizumab
Normalized name: Gentulizumab
DrugBank: Gentulizumab (DB18148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
Study: NCT04545151
Drug: Verapamil SR 120 mg
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily
Study: NCT05410275
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental group Each patient will receive successively over 3 distinct periods the 3 doses of rivaroxaban to be evaluated, i.e., 5 mg, 10 mg, and 15 mg as a single daily dose (once daily over 3 days for each dose).
Study: NCT06630364
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane
Study: NCT05162469
Drug: SHR-1909 injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
Study: NCT05527808
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ,intravenous injection ,Q3W 2-4 cycles
Study: NCT05527808
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2,intravenous injection ,Q3W 2-4 cycles
Study: NCT05527808
Drug: or carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
Study: NCT06116968
Drug: Aficamten
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-20mg
Study: NCT03127605
Drug: Inotuzumab Ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06676475
Drug: MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).
Study: NCT06676475
Drug: BOTOX-A
Normalized name: botulinum toxin type A Injection [Botox]
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 2ml of BTX
Study: NCT06676475
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml of saline
Study: NCT05423496
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimization of MMF
Study: NCT06358599
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
Study: NCT05184569
Drug: Verdiperstat
Normalized name: Verdiperstat
DrugBank: Verdiperstat (DB12440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, extended release (ER) tablet
Study: NCT06490536
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is used as part of the chemotherapy regimens for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Oxaliplatin 130 mg/m² is given intravenously on day 1, in combination with capecitabine 1000 mg/m² taken orally twice daily on days 1-14 of each 21-day cycle.~FOLFOX Regimen: Oxaliplatin 85 mg/m² is administered intravenously on day 1, alongside folinic acid 400 mg/m² and fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~Dosages are standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months.
Study: NCT06490536
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Folinic acid (leucovorin) 400 mg/m² is given intravenously on day 1, in combination with oxaliplatin 85 mg/m² IV on day 1 and fluorouracil 400 mg/m² IV bolus followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of folinic acid is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results, typically up to 6 months.
Study: NCT06490536
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial, specifically for those with MGMT-negative tumors. It is administered in the following way:~TEMIRI Regimen: Temozolomide 150-200 mg/m² is taken orally once daily on days 1-5 of each 28-day cycle, in combination with irinotecan 250 mg/m² administered intravenously on day 1 of each cycle.~The dosage of temozolomide is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06490536
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan is used as part of the tailored chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following ways:~TEMIRI Regimen: Irinotecan 250 mg/m² is administered intravenously on day 1 of each 28-day cycle, in combination with temozolomide 150-200 mg/m² taken orally once daily on days 1-5.~FOLFIRI Regimen: Irinotecan 180 mg/m² is given intravenously on day 1, in combination with folinic acid (leucovorin) 400 mg/m² IV, fluorouracil 400 mg/m² IV bolus, followed by 2400 mg/m² IV infusion over 46 hours, in each 14-day cycle.~The dosage of irinotecan is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT00362219
Drug: Morphine - .25 mg
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gel with 0.25 mg morphine per 100cm2 square of wound.
Study: NCT00362219
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel with 0.75 mg morphine per 100cm2 square of wound.
Study: NCT00362219
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel with 1.25 mg morphine per 100cm2 square of wound.
Study: NCT06490536
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Nivolumab: 3 mg/kg is given intravenously every 2 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06490536
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is used as part of the tailored immunotherapy regimen for patients with ctDNA+ results, specifically for those with MSI-H/MMRd tumors in the SAGITTARIUS trial. It is administered in the following way:~Ipilimumab: 1 mg/kg is given intravenously every 6 weeks. This dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06490536
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Trastuzumab: 8 mg/kg as an initial intravenous (IV) loading dose, followed by 6 mg/kg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06490536
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with HER2-amplified tumors in the SAGITTARIUS trial. It is administered in the following way:~Pertuzumab: 840 mg as an initial intravenous (IV) loading dose, followed by 420 mg IV every 3 weeks.~The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06490536
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab is used as part of the tailored targeted therapy regimen for patients with ctDNA+ results, specifically for those with multiple wild-type tumors (MSS/MMRp extended RAS/RAF wild-type) in the SAGITTARIUS trial. It is administered in the following way:~Panitumumab: 6 mg/kg is given intravenously every 2 weeks. The dosage is standardized, while the duration of treatment can be adjusted based on patient response and liquid biopsy results.
Study: NCT06530251
Drug: AK112
Normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a predefined dose and date.
Study: NCT06530251
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a predefined dose and date.
Study: NCT06530251
Drug: AK127
Normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Following a predefined dose and date.
Study: NCT05616494
Drug: Docetaxel for injection (Albumin-bound)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
Study: NCT05300672
Drug: fibrinogen infusion
Normalized name: fibrinogen
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
Study: NCT06530251
Drug: AK130
Normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following a predefined dose and date.
Study: NCT06530251
Drug: Sintilimab Injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the local label direction.
Study: NCT06530251
Drug: Bevacizumab biosimilar
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following the local label direction.
Study: NCT06020300
Drug: Oral Colchicine 0.6 mg
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-Inflammatory Effects
Study: NCT06487000
Drug: EC-18
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, QD
Study: NCT05469165
Drug: Cyproheptadine 4 Mg Oral Tablet
Normalized name: cyproheptadine 4 mg oral tablet
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine treatment for 3 months
Study: NCT06414395
Drug: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
Normalized name: dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
Study: NCT06509009
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimotuzumab, toripalimab, gemcitabine, cisplatin
Study: NCT05122026
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As included in arm/group description
Study: NCT05122026
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As included in arm/group description
Study: NCT01130259
Drug: iniparib
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
Study: NCT06205836
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive cemiplimab (350 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Study: NCT06205836
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive fianlimab (1600 mg administered IV) on Day 1 of each 21 day cycle for a total of 4 cycles of treatment.
Study: NCT06323369
Drug: Tislelizumab（neoadjuvant）
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT04836962
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
Study: NCT06323369
Drug: Cisplatin （neoadjuvant）
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06323369
Drug: Nab-paclitaxel （neoadjuvant）
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06323369
Drug: Cisplatin（adjuvant）
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06323369
Drug: Tislelizumab（adjuvant）
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06323369
Drug: Carboplatin（neoadjuvant）
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06323369
Drug: Carboplatin（adjuvant）
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05785325
Drug: RC48-ADC plus Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
Study: NCT05127525
Drug: IRX-101
Normalized name: IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRX-101 to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Study: NCT05127525
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Providone-Iodine Betadine to prevent infectious endophthalmitis following intravitreal injection therapy (IVT)
Study: NCT05072249
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take Home Naloxone for reversing opioid overdose
Study: NCT05071482
Drug: Flumatinib
Normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
Study: NCT05071482
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
Study: NCT06273943
Drug: Cabotegravir Tablets, for oral use.
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
Study: NCT04689932
Drug: Triferic AVNU
Normalized name: FERRIC PYROPHOSPHATE CITRATE 1.5 mg in 1 mL INTRAVENOUS SOLUTION [Triferic AVNU]
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric Pyrophosphate Citrate
Study: NCT06273943
Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
Study: NCT04971200
Drug: Tildrakizumab
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 100mg subcutaneous injections Q4W
Study: NCT05305885
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.